Galapagos nets $285mm via FOPO
Galapagos NV therapies for conditions including cystic fibrosis inflammation fibrosis and osteoarthritis netted $285mm through a public offering in the US of 2.58mm American Depositary Shares at...
View ArticleSolving the gut inflammation puzzle
Inflammatory bowel disease IBD an umbrella term for a number of gut disorders including ulcerative colitis and Crohn's disease remains a clinical challenge. Now researchers have identified a protein...
View ArticleMedical News Today What are the best foods to avoid during a Crohn's disease...
The symptoms of Crohns disease can worsen after eating certain foods while other foods can help improve symptoms. The best foods to eat and avoid differ during a flareup however. We look at foods that...
View ArticleMedical News Today What are the stages of Crohn's disease
Crohn's disease causes chronic inflammation in the digestive tract. Although Crohn's disease tends to get worse over time symptoms can vary considerably and may sometimes disappear for weeks or even...
View ArticleDetecting epigenetic signature may help people stay ahead of IBD
Cincinnati Children's Hospital Medical Center With an estimated 1.6 million people in the US dealing with inflammatory bowel disease IBD physicians can have a hard time telling which newly diagnosed...
View ArticleSolving the Gut Inflammation Puzzle
NewsInflammatory bowel disease an umbrella term for a number of gut disordersincluding ulcerative colitis and Crohns diseaseremains a clinical challenge.
View ArticleEU approval for Mylan and Fujifilm's Humira biosimilar
The European Commission has approved its fifth biosimilar of the worlds bestselling drug Abbvies Humira adalimumab granting marketing authorisation to Mylan and Fujifilm Kyowa Kirin Biologics FFKB...
View ArticleuBiome Announces Expansion into MicrobiomeBased Therapeutics Appoints...
uBiome Opens Therapeutics Headquarters in Cambridge Massachusetts to Support Drug Discovery and Development Initially Focused on Therapeutics for Oncology Autoimmune Disorders Obesity and Metabolic...
View ArticleuBiome Announces $83 Million Series C Financing
uBiome Will Expand Worlds Largest Human Microbiome Database and Advance Product Portfolio Including Drug Discovery & Development uBiome the leader in microbial genomics today announced the...
View Article4D pharma plc 4D Announces Positive Data From Phase 1b Study of Thetanix in...
LEEDS United Kingdom Sept. 24 2018 GLOBE NEWSWIRE 4D pharma plc AIM DDDD a pharmaceutical company leading the development of live biotherapeutics today announces positive topline resu...
View ArticleZappRx Announces Partnership with Dunn Meadow Specialty Pharmacy
Digital health company partners with New Jerseybased specialty pharmacy to speed up prescription access for patients across the U.S. ZappRx a&160;digital health company that streamlines the...
View Article$ARNA Reports Positive Phase 2a Results for Olorinab in Patients with...
$ARNA Reports Positive Phase 2a Results for Olorinab in Patients with Abdominal Pain Associated with Crohn's Disease...
View ArticleGenentechs TECENTRIQ in Combination with Chemotherapy Helped People Live...
First Phase III study to show a cancer immunotherapybased combination significantly improved overall survival OS and progressionfree survival PFS in the initial treatment of extensivestage small cell...
View ArticleArenas Olorinab Demonstrates Positive Phase 2a Results in Patients with...
SAN DIEGO Sept. 24 2018 PRNewswire &8212; Arena Pharmaceuticals Inc. Nasdaq ARNA today announced positive topline results from its Phase 2a trial of olorinab an investigational peripherally...
View ArticleMorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial...
DGAPNews MorphoSys AG Key words Study25.09.2018 2201 The issuer is solely responsible for the content of this announcement.PlaneggMunich Germany September 25 2018 MorphoSys Announces its Licensee...
View ArticleOn A Roll Arena Continues Streak Of Positive Data With Small Crohn&39;s Pain...
Arena announced encouraging data from a small Phase IIa study for oloranib APD371 in abdominal pain associated with Crohn&39;s disease...&160;&160;&160;
View ArticleAlexion Continues Pipeline Rebuilding With $400m Takeout Of Syntimmune
Alexions third deal this year brings privately held Syntimmune and its Phase IbIIa candidate for three IgGmediated rare disorders including...&160;&160;&160;&160;
View ArticleCan Takeda&39;s Alunbrig Take On Roche&39;s Alecensa In FirstLine ALKPositive...
Takeda&39;s Phase III win over Pfizer&39;s Xalkori leaves oncologists cheering but hankering for a headtohead study against Alecensa which is...&160;&160;
View Article